Complete collaborative environment with intuitive interface addresses common analysis challenges to help accelerate transition from scientific discovery to data-driven precision medicine.
BigOmics Analytics, the Swiss biomedical data analysis startup, today announced a collaboration with DNAnexus Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software. As part of the agreement, BigOmics’ collaborative analysis environment, Omics Playground, is now available on the DNAnexus precision health data platform, providing customers with a fully integrated solution to better understand large-scale proteomics and transcriptomics data.
BigOmics is an omics data visualization company. The Omics Playground platform offers intuitive visualization and interpretation tools for exploring RNA sequencing and proteomics data. DNAnexus is the data cloud for precision health, allowing researchers to store, access, and explore large sets of proteomic, transcriptomic, genomic, phenotypic, imaging, and other structured data.
Omics Playground provides DNAnexus users with an interactive interface for visualizing gene and protein expression activity patterns. Biologists can easily and quickly explore their experimental data, while bioinformaticians can offload repetitive tasks.
Moreover, organizations benefit from reduced overhead costs and the fostering of a data-driven scientific culture. Omics Playground standardizes the omics data analysis process, ensuring the delivery of robust and reproducible results.
“Due to the many recent advances in various data generation technologies, life scientists can quickly find themselves buried in large-scale RNA-seq and proteomics data. The analysis process can be slow and current tools are often too difficult to use,” said Murodzhon Akhmedov, PhD, Co-founder and CEO at BigOmics. “This collaboration with DNAnexus combines our intuitive interface with DNAnexus’ industry-leading, integrated, out-of-the-box solution. Any biologist or bioinformatician around the world will be able to perform advanced omics analysis in a few easy clicks.”
Today, DNAnexus has more than 40,000 registered users across 48 countries and actively manages and supports more than 80 petabytes of complex proteomic, genomic, multi-omic, and clinical datasets on behalf of a growing network of collaborators. Its comprehensive cloud platform meets the most rigorous industry standards for data quality, security, privacy, and regulatory compliance.
“DNAnexus remains committed to working with innovative companies like BigOmics that can help make it easier for our customers to harness the power of biomedical data to advance scientific discovery, accelerate precision medicine, and improve patient care,” said Richard Daly, CEO at DNAnexus. “This collaboration will help to eliminate bottlenecks in the analysis of RNA-seq and proteomics data and enable our customers to extract valuable data-driven insights that can lead to the development of new personalized, omics-based treatments.”
Priority medicines (PRIME) is a scheme run by the European Medicines Agency (EMA) to enhance support for the development of medicines that target an unmet medical need. The scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimize development plans and speed up evaluation so these medicines can reach patients earlier EMA CHMP acknowledges that n
LubioScience GmbH, Switzerland’s leading Life Sciences platform, expands its product portfolio with the addition of fresh human blood products and biospecimens provided by Research Donors from the UK.
Preliminary data from 472 nine-month-old infants confirm favorable safety and tolerability profile and demonstrate significant immunogenicity for the four most common pathogen serotypes Results support further development with LimmaTech expecting to initiate the next clinical trial in 2024 Topline results from the completed Phase I/II will be reported in the first half of 2024
InterAx Biotech AG, a product development company pioneering computational pharmacology for drug discovery, announces that the company's most advanced artificial intelligence platform has uncovered novel cellular signaling modes of action which enable InterAx to design efficacious orally available drugs for diabetes, obesity, and immuno oncology. Particularly promising results are coming from the
Its proprietary innovative polymer technology reduces bacterial bioburden without triggering antimicrobial resistance, one of the top global public health threats The Advanced Wound Dressing (AWD) market is valued at 4.5 billion USD and is witnessing increasing demand and technological advancements The company is looking to expand development and commercial collaborations with industry leaders
Vandria is advancing a portfolio of mitophagy inducers to address age-related chronic diseases of the CNS, muscle, lung and liver Innosuisse grant totalling CHF 2.5M (€ 2.7M) to support early clinical development plan for lead CNS mitophagy drug candidate VNA-318 that has the potential to treat cognitive impairment, dementia, Alzheimer’s and Parkinson’s Disease Eurostars grant totalling €1